Longitudinal MR-based proton-density fat fraction (PDFF) and T2* for the assessment of associations between bone marrow changes and myelotoxic chemotherapy - Summary - MDSpire
Advertisement
Longitudinal MR-based proton-density fat fraction (PDFF) and T2* for the assessment of associations between bone marrow changes and myelotoxic chemotherapy
To evaluate the influence of myelotoxic chemotherapy on PDFF and T2* changes and compare these changes to the current standard imaging techniques for osteoporosis, specifically dual-energy X-ray absorptiometry (DXA) and quantitative CT.
Key Findings:
Myelotoxic chemotherapy leads to increased fat fractions in yellow marrow and reduced hematopoiesis.
MRI-based PDFF is a reliable tool for assessing bone marrow fat without radiation exposure.
A negative correlation exists between bone marrow fat fraction and bone mineral density.
Interpretation:
The study suggests that PDFF and T2* measurements can serve as non-invasive biomarkers for assessing bone marrow changes in patients undergoing myelotoxic chemotherapy.
Limitations:
Retrospective design may introduce selection bias, potentially affecting the validity of the findings.
Limited sample size of 19 patients may restrict the generalizability of the results.
Exclusion of patients receiving prior myelotoxic chemotherapy or abdominal radiotherapy may limit the applicability of findings.
Conclusion:
MRI-based PDFF and T2* measurements could address the diagnostic gap in osteoporosis treatment for oncologic patients, facilitating early detection and management of bone marrow changes.
by Felix G. Gassert, Julia Kranz, Florian T. Gassert, Benedikt J. Schwaiger, Christian Bogner, Marcus R. Makowski, Leander Glanz, Jonathan Stelter, Thomas Baum, Rickmer Braren, Dimitrios C. Karampinos, Alexandra S. Gersing
